Mallinckrodt Acquires Therakos for $1.3 Billion
A Mallinckrodt subsidiary is acquiring immunotherapy company Therakos for $1.3 billion, in a deal expected to close by the end of the third quarter.
Therakos is a leader in autologous immune cell therapy delivered through extracorporeal photopheresis. Its Cellex system is approved by the FDA for the palliative treatment of skin manifestations of cutaneous T-cell lymphoma.
With the transaction, Mallinckrodt expands its specialty brands portfolio and diversifies its hospital offerings with a system already used in hospitals and major medical centers in more than 25 countries.
Therakos’ commercial team will be integrated into Mallinckrodt’s critical care organization within its hospital specialty brands business, taking advantage of its sales, marketing, training and clinician support staff. — John Bechtel